CA3172601A1 - Preparation of cyclosporin derivatives - Google Patents

Preparation of cyclosporin derivatives Download PDF

Info

Publication number
CA3172601A1
CA3172601A1 CA3172601A CA3172601A CA3172601A1 CA 3172601 A1 CA3172601 A1 CA 3172601A1 CA 3172601 A CA3172601 A CA 3172601A CA 3172601 A CA3172601 A CA 3172601A CA 3172601 A1 CA3172601 A1 CA 3172601A1
Authority
CA
Canada
Prior art keywords
compound
process according
formula
equivalents
copper
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3172601A
Other languages
English (en)
French (fr)
Inventor
Ching-Pong Mak
Fashu MA
Daofei LI
Xiao Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Farsight Medical Technology Shanghai Co Ltd
Original Assignee
Farsight Medical Technology Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farsight Medical Technology Shanghai Co Ltd filed Critical Farsight Medical Technology Shanghai Co Ltd
Publication of CA3172601A1 publication Critical patent/CA3172601A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Analytical Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3172601A 2020-03-26 2021-03-25 Preparation of cyclosporin derivatives Pending CA3172601A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2020081295 2020-03-26
CNPCT/CN2020/081295 2020-03-26
CNPCT/CN2021/078391 2021-03-01
CN2021078391 2021-03-01
PCT/CN2021/083016 WO2021190604A1 (en) 2020-03-26 2021-03-25 Preparation of cyclosporin derivatives

Publications (1)

Publication Number Publication Date
CA3172601A1 true CA3172601A1 (en) 2021-09-30

Family

ID=77891510

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3172601A Pending CA3172601A1 (en) 2020-03-26 2021-03-25 Preparation of cyclosporin derivatives
CA3172535A Pending CA3172535A1 (en) 2020-03-26 2021-03-25 Cyclophilin inhibitors and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3172535A Pending CA3172535A1 (en) 2020-03-26 2021-03-25 Cyclophilin inhibitors and uses thereof

Country Status (11)

Country Link
US (3) US20230174583A1 (https=)
EP (2) EP4126905A4 (https=)
JP (2) JP7761578B2 (https=)
KR (2) KR20220158761A (https=)
CN (2) CN115335389A (https=)
AU (1) AU2021240762A1 (https=)
BR (1) BR112022018929A2 (https=)
CA (2) CA3172601A1 (https=)
IL (1) IL296586B1 (https=)
MX (1) MX2022011697A (https=)
WO (2) WO2021190601A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111449050A (zh) * 2019-01-20 2020-07-28 睿诺医疗科技（上海）有限公司 环孢菌素类似物及其用途
AU2020363688A1 (en) 2019-10-12 2022-04-21 Farsight Medical Technology (Shanghai) Co., Ltd. Treatment and prevention of nephrotoxin-induced kidney injuries
IL296586B1 (en) * 2020-03-26 2026-04-01 Farsight Medical Tech Shanghai Co Ltd Cyclophilin inhibitors and their uses
AU2021256222A1 (en) 2020-04-15 2022-10-06 Farsight Medical Technology (Shanghai) Co., Ltd. Prevention and treatment of organ injuries
GB202207348D0 (en) * 2022-05-19 2022-07-06 Cypralis Ltd Macrocyclic compounds and uses thereof
WO2024183651A1 (en) * 2023-03-03 2024-09-12 Farsight Medical Technology (Shanghai) Co., Ltd. Treatment and prevention of agent‐induced liver conditions or diseases
KR20260018851A (ko) * 2023-06-02 2026-02-09 파사이트 메디컬 테크놀로지 (상하이) 컴퍼니 리미티드 사이클로필린 저해제 및 그 용도

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0194972B1 (en) 1985-03-11 1992-07-29 Sandoz Ag Novel cyclosporins
FI111730B (fi) 1990-11-02 2003-09-15 Novartis Ag Menetelmä ei-immunosuppressiivisen syklosporiinin valmistamiseksi
AU750245B2 (en) * 1997-10-08 2002-07-11 Aurinia Phamaceuticals Inc. Deuterated cyclosporine analogs and their use as immunomodulating agents
CN1205220C (zh) 1998-06-12 2005-06-08 斯－凯穆公司 新颖的环孢菌素
US6809077B2 (en) 2001-10-12 2004-10-26 Enanta Pharmaceuticals, Inc. Cyclosporin analogs for the treatment of autoimmune diseases
CN100344648C (zh) 2001-10-19 2007-10-24 伊索泰克尼卡股份有限公司 环孢菌素类似物混合物及其在制备免疫调节剂中的用途
US7538084B2 (en) 2003-03-17 2009-05-26 Amr Technology, Inc. Cyclosporins
SI1802650T1 (sl) 2004-10-01 2012-03-30 Scynexis Inc Eter in tioeter substituirani ciklosporinski derivati za zdravljenje in preventivo pred infekcijami s hepatitisom c
ZA200703157B (en) * 2004-10-01 2008-08-27 Scynexis Inc 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
EP2023918B1 (en) * 2006-05-19 2011-03-23 Scynexis, Inc. Cyclosporins for the treatment and prevention of ocular disorders
WO2008143996A1 (en) * 2007-05-18 2008-11-27 Scynexis, Inc. New chemical processes
AU2009276241A1 (en) 2008-07-30 2010-02-04 Ciclofilin Pharmaceuticals Corp. Nonimmunosuppressive cyclosporine analogue molecules
KR20110111321A (ko) * 2009-01-30 2011-10-10 이난타 파마슈티칼스, 인코포레이티드 Ｃ형 간염을 예방하거나 치료하기 위한 사이클로스포린 유사체
US8481483B2 (en) 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
WO2011082289A1 (en) * 2009-12-30 2011-07-07 Scynexis Inc. Cyclosporine analogues
WO2012009715A2 (en) * 2010-07-16 2012-01-19 S&T Global Inc. Novel cyclosporin derivatives for the treatment and prevention of a viral infection
US9890198B2 (en) * 2010-12-03 2018-02-13 S&T Global Inc. Cyclosporin derivatives and uses thereof
BR112013014890B1 (pt) 2010-12-15 2023-10-24 Contravir Pharmaceuticals, Inc Composto análogo de moléculas pertencentes à família ciclosporina, composição farmacêutica compreendendo o mesmo, uso terapêutico ou profilático do referido composto e processos para a preparação dos mesmos
DE102011111991A1 (de) * 2011-08-30 2013-02-28 Lead Discovery Center Gmbh Neue Cyclosporin-Derivate
GB201217560D0 (en) 2012-10-02 2012-11-14 Mitopharm Ltd Novel cyclic depsipeptide compounds and their uses
US20140212381A1 (en) * 2012-10-19 2014-07-31 Scynexis, Inc. Macrocycles
GB201222455D0 (en) * 2012-12-13 2013-01-30 Perioc Ltd Novel pharmaceutical formulations and their use in the treatment of periodontaldisease
GB201414806D0 (en) 2014-08-20 2014-10-01 Ucl Business Plc Cyclosporin conjugates
WO2017004304A1 (en) * 2015-06-30 2017-01-05 Cypralis Limited Novel macrocycles
CN106902346A (zh) * 2015-12-23 2017-06-30 中美华世通生物医药科技（武汉）有限公司 药物组合物及其制药用途
CN106902347A (zh) * 2015-12-23 2017-06-30 中美华世通生物医药科技（武汉）有限公司 亲环孢素抑制剂的用途
CN118324867A (zh) * 2016-05-17 2024-07-12 美国科技环球有限公司 新型环孢菌素衍生物及其用途
GB201711749D0 (en) * 2017-07-21 2017-09-06 Cypralis Ltd Cyclosporin analogues and uses thereof
WO2020037530A1 (en) * 2018-08-22 2020-02-27 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Crystalline form of compound and uses thereof in medicine
CN111449050A (zh) * 2019-01-20 2020-07-28 睿诺医疗科技（上海）有限公司 环孢菌素类似物及其用途
IL296586B1 (en) * 2020-03-26 2026-04-01 Farsight Medical Tech Shanghai Co Ltd Cyclophilin inhibitors and their uses

Also Published As

Publication number Publication date
EP4126905A1 (en) 2023-02-08
JP2023518777A (ja) 2023-05-08
MX2022011697A (es) 2022-10-07
TW202144379A (zh) 2021-12-01
US20230174583A1 (en) 2023-06-08
JP7776435B2 (ja) 2025-11-26
US20240352074A1 (en) 2024-10-24
EP4126904A4 (en) 2024-05-29
IL296586A (en) 2022-11-01
CN115335389A (zh) 2022-11-11
IL296586B1 (en) 2026-04-01
JP7761578B2 (ja) 2025-10-28
CN115298199A (zh) 2022-11-04
US20230110497A1 (en) 2023-04-13
US12522634B2 (en) 2026-01-13
KR20220158760A (ko) 2022-12-01
BR112022018929A2 (pt) 2022-12-06
JP2023518776A (ja) 2023-05-08
AU2021240762A1 (en) 2022-10-06
WO2021190601A1 (en) 2021-09-30
EP4126904A1 (en) 2023-02-08
CA3172535A1 (en) 2021-09-30
WO2021190604A1 (en) 2021-09-30
US12060440B2 (en) 2024-08-13
KR20220158761A (ko) 2022-12-01
EP4126905A4 (en) 2024-05-29

Similar Documents

Publication Publication Date Title
CA3172601A1 (en) Preparation of cyclosporin derivatives
EP0916646B1 (en) Process for the preparation of a substituted 2,5-diamino-3-hydroxyhexane
CA2007117A1 (en) Beta-adrenergic agonists
JP7144873B2 (ja) スガマデクスナトリウム塩の製造方法
CN114127076A (zh) 吗啡喃衍生物的制造方法
WO2021009034A1 (en) 3-[2(r)-amino-2-phenylethyl]-5-(2-fluoro-3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-1h-pyrimidine-2,4(1h,3h)-dione hydrochloride salt (i) in solid form, process for preparing same, and use thereof in the synthesis of elagolix
JP4150081B2 (ja) ２―イミダゾリン―５―オンの調製用中間体
CA2949334A1 (fr) Composes de type 5-acylsulfanyl-histidine en tant que precurseurs des 5-sulfanylhistidines correspondantes et de leurs disulfures
JP2010508334A (ja) アミノベンゾシクロヘプテン誘導体、その調製方法及び治療におけるその使用
JP6629209B2 (ja) 心血管系疾患治療のための医薬品を調製する方法、及びその調製に用いられる中間体を調製する方法
JP2007532538A (ja) プロブコール誘導体の製造方法
US20150246869A1 (en) Process for Preparing Cinacalcet and Pharmaceutically Acceptable Salts Thereof
EP2888250A1 (en) Process for the synthesis of substituted gamma lactams
WO2012062918A1 (en) Process for the preparation of 3-aroyl-5-aminobenzofuran derivatives
JP2025060464A (ja) 抗パーキンソン病薬の結晶形態の調製
CN117858866A (zh) 用于制备色胺衍生物的方法
US7345191B2 (en) Process for preparation of probucol derivatives
JP2858015B2 (ja) 光学活性な１―アルキルアミノ―３―アリールオキシ―２―プロパノール類の製造方法
JP4004082B2 (ja) 環状ニトログアニジン誘導体の製造法
JP2011506443A (ja) 癌を処置するための化合物および方法
JP4193437B2 (ja) 光学活性カルボン酸類
JPWO1994019359A1 (ja) メタンジホスホン酸化合物の製造方法
JP5176452B2 (ja) 光学活性なテトラヒドロピラニルグリシン化合物の製造方法
WO2020129591A1 (ja) アミドアルコール化合物の製造方法
JP2020526523A (ja) 方法

Legal Events

Date Code Title Description
P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250310

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250311

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250311

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250317

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250317

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250317

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250331

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250331

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250331

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250429

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250514

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260316

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260316